Anti-IL17 therapies for psoriasis. (2nd January 2019)

• Record Type: Journal Article
• Authors: Silfvast-Kaiser, Annika; Paek, So Yeon; Menter, Alan
• Is Part Of: Expert opinion on biological therapy. Volume 19:Number 1(2019)
• Page Start: 45
• Page End: 54
• Publication Date: 2019-01-02
• Subjects: Psoriasis -- biologics -- interleukin-17 inhibitors -- secukinumab -- ixekizumab -- brodalumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2019.1555235
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Interleukin-17 (IL-17) is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of plaque psoriasis. As a result, focus in clinical trials has undergone a shift towards disease specific targets, with the goals of more effective treatment and reduction in the incidence of serious adverse events. Areas covered : Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one against the IL-17 receptor (brodalumab) are approved for the treatment of moderate-to-severe plaque psoriasis. Herein, the clinical efficacy, safety and tolerability of each is reviewed by summarizing the existing literature (found via PubMed database). Expert commentary : The development and approval of the IL-17 inhibitor agents secukinumab, ixekizumab, and brodalumab has expanded psoriatic treatment with effective options, validating the importance of the pro-inflammatory role of IL-17 psoriatic pathophysiology. Biologic treatment options for psoriasis will continue to grow, especially IL-17 and IL-23 related agents, with an increasing specificity of agents to be available in the future.